Sep. 8 at 1:23 PM
$VERU PR takeaway & tactical update...
Headline momentum around advancing oral sabizabulin into a planned Phase 2 for daraxonrasib-resistant pancreatic cancer is catching attention this morning, but my instinct tells me investors may treat this news with a degree of caution once the dust settles.
A few realities to keep in mind:
- Preclinical stage: At this stage, this remains in vitro cell line work. The broader market historically hesitates to assign real valuation multiples to preclinical oncology data until clinical trial execution and human efficacy are established.
- Cash runway & pipeline costs: Veru holds ~
$23.9M in cash, which management has specifically guided to fund ops through the Phase 2b PLATEAU obesity interim read in Q1 2027. Adding a full Phase 2 oncology program adds capital demand, keeping secondary or ATM financing risk lingering on high-volume spikes.
- Timeline: FWIW, dosing isn't kicking off tomorrow... a pre-IND meeting with the FDA is slated for Q4 2026 just to establish the trial's scope and design.
Personally, I’m treating this morning's move as a sell-the-news event. Stepped aside into the premarket pop (+8%) to protect capital. I may or may not end up regretting that exit but, for me, disciplined risk management always comes first. Waiting to see where this trades/settles in the coming days and if the chart establishes a new base. Just sharing my thoughts and positioning. NFA
